Commentary · 21 Feb 2026
Research articlePublished 2016
Improved Antitumor Effect of Survivin Responsive Conditional Replication Adenovirus in Combination with Cisplatin in Lung Cancer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Object: A chemotherapy drug such as cisplatin or diamminedichloroplatinum (DDP) is an alkylating agent that is widely used to treat many cancers despite its associated severe side effects. Biotherapy involving oncolytic adenoviruses also has proven anti-tumor efficacy. Survivin, an inhibitor of apoptosis is highly expressed in tumor cells. The aim of this study was to examine the synergistic effects of combined therapy including Survivin-responsive adenovirus and cisplatin in the treatment of lung cancer and to further reveal the mechanism involved. Methods: Two lung cancer cell lines, NCI-H292 and NCI-H66, were obtained from the cell collections center at CAS-China. A Survivin-responsive conditionally replicating adenovirus (CRAd) with a deleted E1B region was developed in our laboratory. The anti-tumor efficacy of combined in vitro and in vivo treatment (DDP plus CRAd) was assessed with MTS assays and a subcutaneous mouse model, respectively. The expression of Coxsackie adenoviral receptor (CAR) on cancer cell surfaces was determined through RT-PCR analysis. Results: The MTS assays revealed maximal tumor inhibition rates of 70% and 60% obtained when DDP and CRAd were used at doses of 64 μg/ml and 800 MOI, respectively. Nearly identical inhibition was observed with a combined treatment approach (DDP+CRAd) with lower doses of DDP (4 μg/ml) and CRAd (100 MOI). In vivo studies also revealed that tumor suppression was significantly higher in the combined treatment group. RT-PCR analysis showed that CAR expression was much higher in the combined treatment groups. Conclusion: Our study indicates that the combined treatment approach, including survivin promoter-regulated CRAd and DDP, is therapeutically more effective against lung cancer not only because of the synergistic tumorinhibition of the two treatments but also because of the additional tumor-specificity of CRAd resulting from Survivin promoter insertion.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Li Yanan”
- BylineArticles whose byline prints “Ali Sakhawat”
- BylineArticles whose byline prints “Ling Ma”
- BylineArticles whose byline prints “Shensen Wang”
- BylineArticles whose byline prints “Yinghui Huang”
